Duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors: A prospective, multicentric cohort study

被引：0
|
作者：
Su, J-Y. [1 ]
Liu, S. [2 ]
Xu, X-L. [3 ]
Ou, J-J. [4 ]
Li, L. [1 ]
Ma, Y-L. [5 ]
Ma, L. [1 ]
Zhong, J-H. [1 ]
机构：
[1] Guangxi Med Univ, Canc Hosp, Hepatobiliary Surg, Nanning, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 8, Hepatobiliary Surg, Guigang, Peoples R China
[3] Peoples Hosp Wuzhou, Med Records & Stat Room, Wuzhou, Peoples R China
[4] Wuzhou Peoples Hosp, Hepatobiliary Surg, Wuzhou, Peoples R China
[5] Guangxi Med Univ, Canc Hosp, Pathol, Nanning, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.233
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
213P
引用
收藏
页码：S1485 / S1486
页数：2
相关论文
共 50 条
  • [21] Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study
    Wang, Charlie
    Zoungas, Sophia
    Yan, Mabel
    Wolfe, Rory
    Haydon, Andrew
    Shackleton, Mark
    Voskoboynik, Mark
    Moore, Maggie
    Andrews, Miles C.
    Nicholls, Stephen J.
    Mar, Victoria
    CARDIO-ONCOLOGY, 2022, 8 (01)
  • [22] Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort
    Domblides, C.
    Monnet, I.
    Mazieres, J.
    Barlesi, F.
    Gounant, V.
    Baldacci, S.
    Mennecier, B.
    Toffart, A. C.
    Valette, C. Audigier
    Doucet, L.
    Giroux-Leprieur, E.
    Guisier, F.
    Molinier, O.
    Perol, M.
    Pichon, E.
    Robinet, G.
    Grangerat, D. Templement
    Ruppert, A-M.
    Wislez, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 406 - 406
  • [23] Adjuvant PD-1 inhibitors improve recurrence and survival outcomes in high-risk hepatocellular carcinoma patients after curative hepatectomy
    Shen, Xuehan
    Yan, Wei
    Zhang, Erlei
    Zhang, Zhiwei
    Zhang, Zunyi
    Dong, Hanhua
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2025, 30 (01)
  • [24] Postoperative adjuvant immunotherapy for high-risk hepatocellular carcinoma patients
    Zhang, Wei-Qiao
    Zhang, Qiao
    Tan, Li
    Guan, Zhi-Feng
    Tian, Feng
    Tang, Hong-Tao
    He, Kun
    Chen, Wei-Qiang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [25] The efficacy and safety of tislelizumab as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after radical reaction
    Peng, N.
    Su, J-Y.
    Liu, S.
    Li, L.
    Ma, L.
    Zhong, J-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1487 - S1487
  • [26] Combined immune checkpoint inhibition for high-risk urothelial carcinoma
    Tregunna R.
    Nature Reviews Urology, 2020, 17 (12) : 658 - 658
  • [27] RISK FACTORS OF BIPOLAR DISORDERS AND MDD IN A PROSPECTIVE HIGH-RISK COHORT STUDY
    Preisig, Martin
    Rudaz, Dominique
    Marquet, Pierre
    Aubry, Jean-Michel
    Vandeleur, Caroline
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2019, 58 (10): : S342 - S342
  • [28] Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma
    Ferraresi, Virginia
    Vari, Sabrina
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (03)
  • [29] Efficacy of adjuvant chemotherapy for endometrial carcinoma with high-risk factor for recurrence
    Hasuo, Y
    Nishida, T
    Fujiyoshi, K
    Kuromatsu, H
    Eguchi, H
    Sugiyama, T
    Tanaka, H
    Yakushiji, M
    ONCOLOGY REPORTS, 1996, 3 (05) : 907 - 910
  • [30] Radiotherapy with or without Immune checkpoint inhibitors and tyrosine kinase inhibitors in hepatocellular carcinoma with severe macrovascular invasion: A retrospective cohort study
    Tang, Q-Q.
    Deng, Z-J.
    Ma, L.
    Zhong, J-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1493 - S1493
12345